Season’s Greetings!

Dear Readers, On behalf of everyone at biotuesdays.com, I would like to wish you all a Joyous Christmas and a Happy New Year.  We are taking a short break to spend time with family and friends this holiday season.  But, we will be back in full swing with our next Tuesday Feature on January 5, [...]

Resverlogix begins Phase 2 atherosclerosis trial

Resverlogix (TSX:RVX) has begun dosing patients two months ahead of schedule in a Phase 2 clinical trial to examine its RVX-208 therapy as a treatment for atherosclerosis in patients with stable coronary artery disease (CAD). Led by the Cleveland Clinic, the double-blind, placebo-controlled Assert study will administer RVX-208 to about 280 patients with stable CAD [...]

Cash-rich Paladin on the acquisition trail

Paladin Labs (TSX:PLB) is sitting on a war chest of some $97 million that’s growing by the quarter and itching to be deployed. “We’re going to invest in opportunities with a high return on investment,” CEO Jonathan Goodman, says in an exclusive interview with biotuesdays.com.  “But I’m not going to bet the company on a [...]

Labopharm inks U.K. distribution pact

Labopharm has signed an agreement with Merck Sharp & Dohme (MSD) of Britain for the distribution and marketing of Labopharm’s once-daily tramadol pain drug, Tradorec XL in England, Northern Ireland, Scotland, Wales, the Channel Islands and the Isle of Man. Under the accord with the British unit of Merck (NYSE:MRK), Labopharm will supply MSD with [...]

Thallion in $150-million pact to develop Shigamabs

Thallion Pharmaceuticals (TSX:TLN) is teaming up with LFB Biotechnologies of France to develop Shigamabs, Thallion’s product candidate for the treatment of Shigatoxin-producing bacterial, or STEC, infection. The accord, which is expected to close in the first quarter, provides for immediate funding by LFB of costs associated with re-initiating the Shigamabs program. In a statement, Thallion [...]

Human form of mad cow disease identified in new genetic group

New genetic information about the human version of mad cow disease (vCJD) has heightened concerns in Britain that there are more carriers of the fatal disease than originally thought. According to the BBC, scientists say a 30-year-old man Grant Goodwin, who is believed to have died of vCJD earlier this year, belonged to a genetic [...]

Labopharm files tramadol-acetaminophen drug in Europe

Labopharm (TSX:DDS) has initiated the regulatory approval process for its twice-daily tramadol-acetaminophen formulation in Europe under a decentralized procedure (DCP) system. “Initiating the regulatory approval process in Europe builds on our recently established marketing partnership with Grenenthal GmbH,” Labopharm CEO James Howard-Tripp said in a statement. “It is our intention to commercialize our twice-daily tramadol-acetaminophen [...]

3M to distribute TSO3 sterilizer

TSO3 (TSX:TOS) has signed an agreement with 3M to be the exclusive distributor of its Sterizone 125L sterilization system. The accord “pairs innovation in technology with innovation in marketing, sales and service on a global scale,” TSO3 CEO Ric Rumble said in a statement.  “It supports 3M’s existing Infection Prevention business strategy, while significantly enhancing [...]

Resverlogix in $25 million standby financing

Resverlogix has signed a standby equity distribution agreement with YA Global Master SPV, a fund managed by Yorkville Advisors, which gives Resverlogix an option to sell up to $25-million of common shares to YA. “This agreement will provide Resverlogix with the flexibility to draw strategic amounts of capital at its discretion,” Resverlogix CEO Donald McCaffrey [...]

Versant starts iCo at “buy”

Versant Partners has initiated coverage of iCo Therapeutics (TSX-Venture:ICO) with a “buy” rating and 12-month price target of $1.80.  The shares closed Monday at 59 cents. iCo is an early-stage drug developer focused on in-licensing preclinical or Phase 1 drugs targeting ocular diseases.  Its lead antisense drug iCo-007 is in Phase 1/2 testing for diabetic [...]

Next Page »